Business Context and Reporting Period
Company: Adagio Medical Holdings, Inc. (ADGM)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: Adagio is a medical technology company developing ablation technologies for cardiac arrhythmias, specifically ventricular tachycardia (VT), using its proprietary Ultra-Low Temperature Cryoablation (ULTC) platform. The company completed a business combination with ARYA Sciences Acquisition Corp IV on July 31, 2024. As of the reporting date, the company is an Emerging Growth Company and a Smaller Reporting Company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | As of Sept 30, 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(10,118) | $(21,778) | N/A |
| Operating Loss | $(5,721) | $(17,922) | N/A |
| Research & Development Expenses | $2,774 | $8,404 | N/A |
| Selling, General & Admin Expenses | $2,916 | $8,892 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $4,673 |
| Convertible Notes Payable (Fair Value) | N/A | N/A | $21,191 |
| Accumulated Deficit | N/A | N/A | $(92,303) |
| Net Cash Used in Operating Activities | N/A | $(14,876) | N/A |
Note: Revenue was nil for the period due to a pause in commercial activity in Europe and the repurchase of previously sold inventory.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to $0 for the three and nine months ended September 30, 2025, compared to $132,000 and $333,000 in the comparable 2024 periods. This decrease is attributed to an inventory buyback associated with a pause in European commercial operations.
- Net Loss Increase: Net loss for the three months ended September 30, 2025, was $(10.1) million, compared to a net income of $3.6 million in the same period in 2024. The swing is primarily driven by non-cash fair value adjustments on convertible notes and warrant liabilities, which shifted from gains in 2024 to losses in 2025.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased by 62.5% year-over-year for the three-month period, largely due to a "corporate prioritization initiative" implemented in February 2025 that reduced headcount.
- Debt Fair Value: The fair value of convertible notes payable increased from $17.2 million at December 31, 2024, to $21.2 million at September 30, 2025, resulting in a $3.5 million loss in the current quarter.
Guidance, Outlook, and Risks
- Clinical Progress: The company completed enrollment in its FULCRUM-VT U.S. IDE Pivotal Study in October 2025. Preliminary results showed 97.4% acute clinical success. The company plans to submit results to the FDA for approval in the first half of 2026.
- Capital Raise: In October 2025, the company announced a private placement of common stock and warrants, raising approximately $19 million in gross proceeds (excluding potential warrant exercises). Management believes this, combined with existing cash, is sufficient to fund operations for at least 12 months.
- Going Concern: The company has a history of recurring losses and negative cash flows. While the recent financing mitigates immediate risk, future capital requirements depend on clinical trial outcomes and commercialization success.
- Risk Factors:
- Regulatory Delays: Potential disruptions at the FDA due to government funding issues or personnel changes could delay product approval.
- Trade Policy: Tariffs and international trade restrictions could increase costs for raw materials and manufacturing, impacting margins.
- Corporate Prioritization: The recent workforce reduction carries risks of losing institutional knowledge and decreased morale.
Investor Verification Checklist
- Cash Runway: Verify the closing of the $19 million private placement and confirm the actual cash balance post-closing to validate the 12-month liquidity assertion.
- Convertible Note Terms: Review the specific terms of the $21.2 million Convertible Securities Notes, including the 13% interest rate, conversion price ($10.00), and maturity date, to assess dilution risk and interest obligations.
- European Operations: Confirm the status of the "pause" in European commercial activity and the timeline for resuming sales to understand the path to revenue generation.
- FULCRUM-VT Trial Data: Monitor the release of the six-month primary efficacy endpoint results expected in April 2026, as this is the critical catalyst for FDA approval.
- Stock-Based Compensation: Review the impact of the 2024 Equity Incentive Plan grants (5.7 million awards granted in the first nine months of 2025) on future expense recognition.